Serum Metabolome Alterations in Patients with Nonalcoholic Fatty Liver Disease

Xuemei Wang

Description

Supplementary Data S1: In the negative mode the raw data of metabolites of all participants (149NAFLD and 149HCs).Supplementary Data S2: In the positive mode the raw data of metabolites of all participants (149NAFLD and 149HCs).Supplementary Data S3: Metabolites detected(100NAFLD and 100HCs) in the negative mode in the training set.Supplementary Data S4: Metabolites detected in the positive mode in the training set(100NAFLD and 100HCs).Supplementary Data S5: Differential metabolites between NAFLDs and healthy controls in discovery set.Supplementary Data S6: Differential metabolites between NAFLDs and healthy controls in validation set.Supplementary Data S7: Calculated data for volcanic maps.Supplementary Data S8: Metabolite classification analysis.Supplementary Data S9:metabolites correlation coefficient.Supplementary Data S10:p-value of metabolites.Supplementary Data S11:Brite A of KEGG brite Database.Supplementary Data S12:Brite B of KEGG brite Database.Supplementary Data S13:Brite C of KEGG brite Database.Supplementary Data S14:KEGG metabolic pathway information sheet.Supplementary Data S15:Results of differential metabolite KEGG enrichment analysis.Supplementary Data S16:Results of KEGG pathway topological analysis of the differential metabolites.Supplementary Data S17:32 serum metabolite markersSupplementary Data S18:p-value of Spearman correlation analysis.Supplementary Data S19:rho-value of Spearman correlation analysis.

Citations (0)

Mentions (0)

Metrics

Dataset Index

0.5

FAIR Score

65%

Citations

0

Mentions

0

Metrics Over Time

Publication Details

DOI

Publisher

Mendeley

License

Creative Commons Attribution 4.0 International

Assigned Domain

Subfield

Pharmacology

Field

Medicine

Domain

Health Sciences

Confidence Score

86%

Source

Open Alex

Normalization Factors

FT

40.38

CTw

1.00

MTw

1.00